Tenaya narrows loss 18% to $90.6M, raises $104.7M in two offerings, cuts workforce 28%

Filed March 11, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 10, 2025 · ~1 min read

Key Changes

• high

  Alnylam collaboration signed March 2026: $10M upfront, $1.13B milestone potential for cardiovascular gene target discovery. Validates platform, provides non-dilutive funding.

  Business: Alnylam collaboration verify on EDGAR →
• high

  MyPEAK-1 one-year data showed cardiac troponin I drops up to 74%, hypertrophy reductions 21-39%, all patients reached asymptomatic status. Dose response confirmed in Cohort 2.

  MD&A: MyPEAK-1 efficacy verify on EDGAR →
• high

  Workforce reduced 28% to 70 employees (from 97), R&D headcount down 34%. Severance charges $1.3M in 2025, $1.6M more expected by Q2 2026.

  Business: Employee headcount verify on EDGAR →